Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Bearish
3
Neutral
8
Bullish
3
Bearish
12
Neutral
8
Bullish
26
Bearish
9
Neutral
0
Bullish
23
Discovery themes featuring this stock
Gland Pharma Limited is a prominent player in the global generic injectables market, operating under a B2B model with essential services like contract development and manufacturing across various systems.
The company achieved broad-based revenue growth of 22% YoY in Q3 FY26, reaching INR 16,954 million, driven by both its expansion and integration of Cenexi in France.
Gland Pharma is actively expanding cartridge fill and finish capacities from 40 million to 140 million units, signifying growth potential in its complex product pipeline.
The acquisition of Cenexi increased Gland Pharma's footprint in Europe and enhanced its manufacturing capabilities, leading to a diversified revenue stream.
Strategic initiatives, including partnerships and CDMO contracts, position Gland Pharma for sustained growth, focusing on high-value, differentiated products.
Pharmaceuticals & Biotechnology
Pharmaceuticals
40,049 Cr
Low Risk
39.0
37.2
1.8
3.9
2,574.00
1,575.00
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stock
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1781.10 | 45,090 Cr | 39.51 | 5.59 | 0.34 | 14.15 | 18.58 | 9.63 | ||
2559.85 | 43,202 Cr | 41.70 | 19.05 | 2.24 | 45.69 | 61.23 | 23.96 | ||
3387.75 | 42,278 Cr | 40.04 | 9.34 | 0.83 | 23.33 | 29.09 | 17.16 | ||
2430.90 | 40,049 Cr | 38.98 | 3.87 | 0.82 | 9.92 | 14.02 | 8.21 | ||
1920.00 | 36,490 Cr | 39.48 | 7.37 | 0.19 | 18.67 | 21.76 | 9.79 | ||
1864.00 | 30,311 Cr | 142.31 | 6.14 | 0.00 | 5.75 | 7.39 | 2.31 | ||
3381.00 | 27,579 Cr | 71.41 | 16.68 | 0.07 | 21.54 | 28.77 | 19.52 | ||
| Median: 7 Co. | — | 2430.90 | 40,049 Cr | 40.04 | 7.37 | 0.34 | 18.67 | 21.76 | 9.79 |
Gland Pharma Ltd (GLAND) is currently trading at 2,435.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Gland Pharma Limited is a prominent player in the global generic injectables market, operating under a B2B model with essential services like contract development and manufacturing across various systems. The company achieved broad-based revenue growth of 22% YoY in Q3 FY26, reaching INR 16,954 million, driven by both its expansion and integration of Cenexi in France. Gland Pharma is actively expanding cartridge fill and finish capacities from 40 million to 140 million units, signifying growth potential in its complex product pipeline. The acquisition of Cenexi increased Gland Pharma's footprint in Europe and enhanced its manufacturing capabilities, leading to a diversified revenue stream. Strategic initiatives, including partnerships and CDMO contracts, position Gland Pharma for sustained growth, focusing on high-value, differentiated products.
Over the past 52 weeks, Gland Pharma Ltd has traded between a low of ₹1,575.00 and a high of ₹2,574.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Gland Pharma Ltd has a market capitalization of approximately 40,048.91. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Gland Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 38.98 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 40,048.91 Cr, Gland Pharma Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Gland Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Gland Pharma Ltd is 38.98. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The board meeting was scheduled for Wednesday, January 28, 2026, to consider and approve unaudited results for the quarter and nine months ended December 31, 2025.
Gland Pharma said its Singapore subsidiary signed a share purchase agreement with FPCI Sino French Midcap Fund to acquire 100% of Europe-based Cenexi Group.
The stock rose after Gland Pharma reported a 96.62% YoY increase in Q4 FY26 net profit to Rs 366.7 crore and a 22.31% rise in net sales to Rs 1,742.80 crore.
Consolidated net profit (PAT) rose 96.62% year-on-year to ₹366.7 crore in Q4 FY26.
AGM/EGM Notice
Gland Pharma Ltd published newspaper ads under Regulation 47 notifying its 48th AGM on 2026-08-25 at 11:00 A.M. IST to be held via Video Conferencing / OAVM; advertisements appeared in English and Telugu newspapers.
Earnings Call/Transcript
Gland Pharma will host its Q1 FY27 earnings conference call on 2026-08-10 at 18:30 IST to discuss results for quarter ended June 30, 2026; audio recording and transcript will be available on the company's website after the call.
Earnings Call/Transcript
Gland Pharma to host Q1 FY27 earnings call on 2026-08-10 at 18:30 IST to discuss results for quarter ended June 30, 2026; audio and transcript will be posted on the company website thereafter.
Board Meeting
Gland Pharma Ltd: Board meeting on 2026-08-10 to consider and approve unaudited standalone and consolidated results for quarter ended 30 June 2026; trading window reopens 2026-08-13; investor/analyst call on 2026-08-10 at 18:30 IST.
Board Meeting
Gland Pharma will hold a Board meeting on 2026-08-10 to consider and approve unaudited standalone and consolidated financial results for quarter ended 2026-06-30. Investor/analyst call on 2026-08-10 at 18:30 IST; trading window reopens 2026-08-13.
